

# **Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035**

<https://marketpublishers.com/r/B397791A9DFBEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: B397791A9DFBEN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

### **Global Bullous Pemphigoid Market: Industry Overview**

Bullous pemphigoid, a rare, chronic autoimmune disorder characterized by large, tense blisters on the skin, significantly impacts the quality of life of affected individuals. It primarily affects older adults and can result in severe complications, including secondary skin infections and scarring. The progression of the disease can lead to significant morbidity if not properly managed.

However, challenges including the high cost of these emerging therapies, the variability in patient responses, and limited access to healthcare resources in low- and middle-income countries remain significant barriers. Additionally, the rarity of bullous pemphigoid, combined with the potential for misdiagnosis or delayed diagnosis, particularly in patients with atypical presentations, complicates the treatment landscape. Despite these challenges, the increasing government and private sector investments in dermatological and autoimmune disease research are expected to drive further growth in the BP market.

### **Impact**

Technological advancements in diagnostic imaging, biomarker testing, and telemedicine

are greatly improving the early detection and personalized management of bullous pemphigoid. Innovations such as serological testing, AI-driven models for disease progression, and advanced imaging techniques are enhancing diagnostic accuracy and treatment monitoring. Additionally, the integration of digital health platforms and remote patient management tools is increasing access to care, especially in underserved areas, facilitating continuous monitoring, improving patient adherence to treatment, and enabling more tailored therapeutic approaches for better disease management and outcomes.

Systemic therapies currently hold the highest market share in the bullous pemphigoid market. This is largely due to their widespread use in managing moderate to severe forms of BP, especially in patients with extensive blistering or those not responding to topical treatments. Systemic corticosteroids, such as prednisone, are the cornerstone of BP treatment, often combined with immunosuppressants such as azathioprine or mycophenolate mofetil to reduce inflammation and prevent flare-ups.

North America holds the highest market share in the bullous pemphigoid market, driven by the region's advanced healthcare infrastructure, high rates of early diagnosis, and access to a wide range of treatment options, including systemic therapies and biologic treatments. The U.S. in particular has a well-established dermatology market, with significant investment in autoimmune disease research and development, leading to the availability of innovative therapies.

## Demand – Drivers and Limitations

### Demand Drivers for the Global Bullous Pemphigoid Market:

As bullous pemphigoid primarily affects elderly individuals, the increasing global aging population is a significant driver of demand.

Improved diagnostic methods, such as serological tests and non-invasive imaging techniques, are enabling earlier detection of BP.

The expansion of healthcare infrastructure, particularly in developing countries, along with the growing use of telemedicine and remote monitoring platforms, is increasing patient access to timely and accurate care.

The development of new biologic therapies and the promise of treatments such as rituximab are fuelling demand.

## Limitations for the Global Bullous Pemphigoid Market:

Biologic therapies and specialized treatments for BP are often costly, limiting their accessibility, especially in low- and middle-income countries.

Although biologic therapies are promising, their availability is still limited due to high costs and complex administration.

Patients with BP exhibit differing responses to treatments, complicating treatment regimens and extending the time required for optimal management.

## How can this report add value to an organization?

**Product/Innovation:** This report provides comprehensive insights into the current trends in bullous pemphigoid, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from bullous pemphigoid, improving outcomes and enhancing market penetration.

**Competitive:** A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global bullous pemphigoid market.

## Key Market Players and Competition Synopsis

The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global bullous pemphigoid market.

Leading players in the global bullous pemphigoid market include:

Sanofi

Regeneron Pharmaceuticals

Amgen Inc.

Johnson & Johnson

Chugai Pharmaceutical

Novartis AG

F. Hoffmann-La Roche Ltd

Teva Pharmaceutical Industries Ltd

Astellas Pharma Inc.

Sun Pharmaceutical Industries Ltd

## Contents

Executive Summary  
Scope and Definition  
Market/Product Definition  
Inclusion and Exclusion  
Key Questions Answered  
Analysis and Forecast Note

### **1. GLOBAL BULLOUS PEMPHIGOID MARKET: INDUSTRY ANALYSIS**

1.1 Market Overview and Ecosystem  
1.2 Epidemiological Analysis  
1.3 Key Market Trends  
    1.3.1 Impact Analysis  
1.4 Regulatory Landscape  
1.5 Pipeline Analysis  
1.6 Market Dynamics  
    1.6.1 Overview  
    1.6.2 Market Drivers  
    1.6.3 Market Restraints  
    1.6.4 Market Opportunities

### **2. GLOBAL BULLOUS PEMPHIGOID MARKET (BY THERAPY TYPE), VALUE (\$MILLION), 2023-2035**

2.1 Topical Therapies  
2.2 Systemic Therapies  
2.3 Biologic Therapies  
2.4 Plasmapheresis  
2.5 Immunosuppressants

### **3. GLOBAL BULLOUS PEMPHIGOID MARKET (BY REGION), VALUE (\$MILLION), 2023-2035**

3.1 North America  
    3.1.1 Market Dynamics  
    3.1.2 Market Sizing and Forecast  
    3.1.3 North America Bullous Pemphigoid Market, by Country (\$Million), 2023-2035

3.1.3.1 U.S.

3.1.3.2 Canada

3.2 Europe

3.2.1 Market Dynamics

3.2.2 Market Sizing and Forecast

3.2.3 Europe Bullous Pemphigoid Market, by Country (\$Million), 2023-2035

3.2.3.1 U.K.

3.2.3.2 France

3.2.3.3 Germany

3.2.3.4 Italy

3.2.3.5 Spain

3.2.3.6 Rest-of-Europe

3.3 Asia-Pacific

3.3.1 Market Dynamics

3.3.2 Market Sizing and Forecast

3.3.3 Asia-Pacific Bullous Pemphigoid Market, by Country (\$Million), 2023-2035

3.3.3.1 Japan

3.3.3.2 China

3.3.3.3 India

3.3.3.4 Australia

3.3.3.5 South Korea

3.3.3.6 Rest-of-Asia-Pacific

3.4 Rest-of-the-World

3.4.1 Market Dynamics

3.4.2 Market Sizing and Forecast Rest-of-the-World Bullous Pemphigoid Market, by Type (\$Million), 2023-2035

3.4.3 Rest-of-the-World Bullous Pemphigoid Market, by Country (\$Million), 2023-2035

3.4.3.1 Latin America

3.4.3.2 Middle East and Africa

## **4. COMPETITIVE LANDSCAPE AND COMPANY PROFILES**

4.1 Competitive Landscape

4.1.1 Mergers and Acquisitions

4.1.2 Partnership, Alliances and Business Expansion

4.1.3 New Offerings

4.1.4 Regulatory Activities

4.1.5 Funding Activities

4.2 Company Profiles

#### 4.2.1 Sanofi

##### 4.2.1.1 Overview

##### 4.2.1.2 Top Products / Product Portfolio

##### 4.2.1.3 Top Competitors

##### 4.2.1.4 Target Customers/End-Users

##### 4.2.1.5 Key Personnel

##### 4.2.1.6 Analyst View

#### 4.2.2 Regeneron Pharmaceuticals

##### 4.2.2.1 Overview

##### 4.2.2.2 Top Products / Product Portfolio

##### 4.2.2.3 Top Competitors

##### 4.2.2.4 Target Customers/End-Users

##### 4.2.2.5 Key Personnel

##### 4.2.2.6 Analyst View

#### 4.2.3 Amgen Inc.

##### 4.2.3.1 Overview

##### 4.2.3.2 Top Products / Product Portfolio

##### 4.2.3.3 Top Competitors

##### 4.2.3.4 Target Customers/End-Users

##### 4.2.3.5 Key Personnel

##### 4.2.3.6 Analyst View

#### 4.2.4 Johnson & Johnson

##### 4.2.4.1 Overview

##### 4.2.4.2 Top Products / Product Portfolio

##### 4.2.4.3 Top Competitors

##### 4.2.4.4 Target Customers/End-Users

##### 4.2.4.5 Key Personnel

##### 4.2.4.6 Analyst View

#### 4.2.5 Chugai Pharmaceutical

##### 4.2.5.1 Overview

##### 4.2.5.2 Top Products / Product Portfolio

##### 4.2.5.3 Top Competitors

##### 4.2.5.4 Target Customers/End-Users

##### 4.2.5.5 Key Personnel

##### 4.2.5.6 Analyst View

#### 4.2.6 Novartis AG

##### 4.2.6.1 Overview

##### 4.2.6.2 Top Products / Product Portfolio

##### 4.2.6.3 Top Competitors

- 4.2.6.4 Target Customers/End-Users
- 4.2.6.5 Key Personnel
- 4.2.6.6 Analyst View
- 4.2.7 F. Hoffmann-La Roche Ltd
  - 4.2.7.1 Overview
  - 4.2.7.2 Top Products / Product Portfolio
  - 4.2.7.3 Top Competitors
  - 4.2.7.4 Target Customers/End-Users
  - 4.2.7.5 Key Personnel
  - 4.2.7.6 Analyst View
- 4.2.8 Teva Pharmaceutical Industries Ltd
  - 4.2.8.1 Overview
  - 4.2.8.2 Top Products / Product Portfolio
  - 4.2.8.3 Top Competitors
  - 4.2.8.4 Target Customers/End-Users
  - 4.2.8.5 Key Personnel
  - 4.2.8.6 Analyst View
- 4.2.9 Astellas Pharma Inc.
  - 4.2.9.1 Overview
  - 4.2.9.2 Top Products / Product Portfolio
  - 4.2.9.3 Top Competitors
  - 4.2.9.4 Target Customers/End-Users
  - 4.2.9.5 Key Personnel
  - 4.2.9.6 Analyst View
- 4.2.10 Sun Pharmaceutical Industries Ltd
  - 4.2.10.1 Overview
  - 4.2.10.2 Top Products / Product Portfolio
  - 4.2.10.3 Top Competitors
  - 4.2.10.4 Target Customers/End-Users
  - 4.2.10.5 Key Personnel
  - 4.2.10.6 Analyst View
- 4.2.11 Others

## **5. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Global Bullous Pemphigoid Market Coverage

Figure: Global Bullous Pemphigoid Market Key Trends, Impact Analysis, 2023-2035

Figure: Global Bullous Pemphigoid Market, Patent Analysis, January 2022-May 2025

## List Of Tables

### LIST OF TABLES

Table: Global Bullous Pemphigoid Market (by Therapy Type), \$Million, 2023-2035

Table: Global Bullous Pemphigoid Market (by Region), \$Million, 2023-2035

## I would like to order

Product name: Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/B397791A9DFBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B397791A9DFBEN.html>